- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03605706
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
A Phase III, Multicentered, Randomized, Double-blinded, Parallel Controlled Study to Evaluate Camrelizumab (PD-1 Antibody) in Combination With FOLFOX4 Regimen Versus Placebo in Combination With FOLFOX4 Regime in First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC).
The study is being conducted to evaluate the efficacy and safety of SHR-1210 plus FOLFOX4 in subjects with advanced HCC who have never received prior systemic treatment compared to placebo plus FOLFOX4.
The primary study hyposis is that Camrelizumab combined with FOLFOX4 treatment can improve Overall Survival when compared with placebo in combination with FOLFOX4 Regimen.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Linna Wang, MD
- Telefonnummer: 021-60453196
- E-mail: wanglinna@hrglobe.com
Studiesteder
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210002
- Rekruttering
- 81 Hospital Nanjing
-
Kontakt:
- Shukui Qin, MD
- Telefonnummer: +862580864542
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Has not received prior systemic treatment for their advanced/metastatic HCC. Has measurable disease according to RECIST v1.1. ECOG Performance Status of 0 or 1. Child-Pugh Class A or B with 7 points. Life Expectancy of at least 12 weeks. HBV DNA<500 IU/ml. Adequate organ function: Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug.
Exclusion Criteria:
Known fibrolamellar HCC, Prior malignancy active with the previous 5 years except for locally curable cancers that have been apparently cured.
Known or occurrence of central nervous system (CNS) metastases. Ascites with clinical symptoms. Known or evidence of GI hemorrhage within the past 6 months. Known or occurrence of hemorrhage/ thrombus. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias.
Grade III~IV cardiac insufficiency, according to NYHA criteria or echocardiography check: LVEF<50%.
Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure > 150mmHg, diastolic blood pressure > 90 mmHg).
History of hepatic encephalopathy. Known history of human immunodeficiency virus (HIV) infection. Active infection or an unexplained fever > 38.5°C during screening visits. Prior or planning to organ transplantation including liver transplantation. Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity.
Proteinuria≥ 2+ and 24 hours total urine protein > 1.0 g. Active known, or suspected autoimmune disease. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment.
Any loco-regional therapy to liver (included but not limited: resection, radiotherapy, TAE, TACE, TAI, RFA or PEI) within 4 weeks prior to study.
Known history of hypersensitivity to monoclonal antibodies or any components of the study drugs.
Pregnant or breast-feeding women. According to the investigator, other conditions that may lead to stop the research.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: SHR-1210
SHR-1210+FOLFOX4
|
Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
|
Eksperimentel: CONTROL
SHR-1210+Placebo
|
Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall Survival
Tidsramme: Up to approximately 3 years
|
OS was defined as the time from randomization to death due to any cause
|
Up to approximately 3 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Objective Response Rate (ORR) per RECIST 1.1 in all participants
Tidsramme: Up to approximately 6 months
|
ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1.
|
Up to approximately 6 months
|
Time to Progression (TTP) per RECIST 1.1 in all participants
Tidsramme: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Duration of Response (DoR) per RECIST 1.1 in all participants
Tidsramme: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Disease Control Rate (DCR) per RECIST 1.1 in all participants
Tidsramme: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Progression-free Survival (PFS) per RECIST 1.1 in all participants
Tidsramme: Up to approximately 3 years
|
Up to approximately 3 years
|
|
AE
Tidsramme: Up to approximately 3 years
|
Up to approximately 3 years
|
|
Overall Survival (OS) rate at 9 months and 12 months
Tidsramme: Up to approximately 9 months and 12 months
|
Up to approximately 9 months and 12 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Shukui Qing, MD, China, Jiangsu 81 Hospital Nanjing
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SHR-1210-III-305-HCC
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Avanceret hepatocellulært karcinom
-
Providence Health & ServicesLedigKRAS G12V Mutant Advanced Epithelial Cancers
-
Samsung Medical CenterAfsluttetHER2-positiv Refractory Advanced CancerKorea, Republikken
-
Shanghai Pudong HospitalUTC Therapeutics Inc.Trukket tilbageMesothelin-positive Advanced Refractory Solid TumorsKina
-
Krankenhaus NordwestAfsluttetHer2/Neu Positive Advanced Solid TumorsTyskland
-
Novartis PharmaceuticalsAfsluttetcMET Dysegulation Advanced Solid TumorsØstrig, Danmark, Sverige, Det Forenede Kongerige, Spanien, Tyskland, Holland, Forenede Stater
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRekrutteringKRAS G12C Mutant Advanced Solid TumorsKina
-
D3 Bio (Wuxi) Co., LtdRekrutteringHER-2 Positive Advanced Solid TumorsForenede Stater, Kina
-
AmgenAktiv, ikke rekrutterendeKRAS p.G12C Mutant Advanced Solid TumorsForenede Stater, Frankrig, Canada, Spanien, Belgien, Korea, Republikken, Østrig, Australien, Ungarn, Grækenland, Tyskland, Japan, Rumænien, Schweiz, Brasilien, Portugal
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk Ureter Urothelial Carcinoma | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Metastatisk nyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
Agenus Inc.AfsluttetAvancerede solide kræftformer | Advanced Solid Cancers Refractory to PD-1Forenede Stater
Kliniske forsøg med SHR-1210
-
Tianjin Medical University Cancer Institute and...Ikke rekrutterer endnuEsophageal pladecellekarcinom | Progression til PD-1 antistofKina
-
Jiangsu HengRui Medicine Co., Ltd.Rekruttering
-
The First Affiliated Hospital of Zhengzhou UniversityIkke rekrutterer endnuResektabelt esophageal pladecellekarcinom
-
Qian ChuJiangsu HengRui Medicine Co., Ltd.Rekruttering
-
Guangdong Association of Clinical TrialsIkke rekrutterer endnuIkke-småcellet lungekræft
-
Beijing Sanbo Brain HospitalRekrutteringPrimært centralnervesystem lymfomKina
-
Jiangsu HengRui Medicine Co., Ltd.Afsluttet
-
Guangdong Association of Clinical TrialsUkendt
-
Harbin Medical UniversityJiangsu HengRui Medicine Co., Ltd.Ukendt
-
Jiangsu HengRui Medicine Co., Ltd.Afsluttet